Korro Bio (KRRO) Cash from Operations (2018 - 2026)
Korro Bio's (KRRO) quarterly Cash from Operations came in at 16074000.0 in Q1 2026, up 34.26% YoY from 11972020.96 in Q1 2025, and up 9.2% on a QoQ basis from 17702000.0 in Q4 2025.
Korro Bio (KRRO) Cash from Operations (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Cash from Operations data on file, last reported at 16074000.0 in Q1 2026.
- Quarterly Cash from Operations rose 34.26% year-over-year to 16074000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 70183000.0 (down 12.05% YoY) and the FY2025 annual result came in at 78561000.0, down 30.77% from the prior year.
- Cash from Operations advanced to 16074000.0 in Q1 2026, from 17702000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 7495000.0 in Q4 2024 to a low of 24452000.0 in Q1 2025.
- A 5-year average of 16213941.18 and a median of 16095000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 64.49% — and 2025, when it sank 136.18%.
- Tracing KRRO's Cash from Operations over 5 years: stood at 11027000.0 in 2022, then sank by 91.41% to 21107000.0 in 2023, then surged by 64.49% to 7495000.0 in 2024, then slumped by 136.18% to 17702000.0 in 2025, then advanced by 9.2% to 16074000.0 in 2026.
- The last three Cash from Operations figures came in at 16074000.0 (Q1 2026), 17702000.0 (Q4 2025), and 17179000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Korro Bio | 232.21 Mn | 117.18 Mn | - | -16.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.99 Mn |
| Jun 30, 2026 | -16.99 Mn |
| Mar 31, 2026 | -16.07 Mn |
| Mar 31, 2026 | -16.07 Mn |
| Dec 31, 2025 | -17.70 Mn |
| Dec 31, 2025 | -17.70 Mn |
| Sep 30, 2025 | -17.18 Mn |
| Sep 30, 2025 | -17.18 Mn |
| Jun 30, 2025 | -19.23 Mn |
| Jun 30, 2025 | -19.23 Mn |
| Mar 31, 2025 | -24.45 Mn |
| Mar 31, 2025 | -24.45 Mn |
| Dec 31, 2024 | -7.50 Mn |
| Dec 31, 2024 | -7.50 Mn |
| Sep 30, 2024 | -16.10 Mn |
| Sep 30, 2024 | -16.10 Mn |
| Jun 30, 2024 | -14.59 Mn |
| Jun 30, 2024 | -14.59 Mn |
| Mar 31, 2024 | -21.89 Mn |
| Mar 31, 2024 | -21.89 Mn |